Recent Press Releases

Aclaris Therapeutics Closes $21 Million Series B Financing

MALVERN, Pa.--(BUSINESS WIRE)-- Aclaris Therapeutics, Inc., a privately-held specialty pharmaceutical company, announced today that it has closed on a $21 million Series B financing. Inclusive of...

Calithera Biosciences, Inc. Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2014 -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company, today announced the pricing of its initial public offering of...

Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results

BOSTON, Oct. 1, 2014 -- Intarcia Therapeutics, Inc. today announced successful top-line results from two of its four phase 3 clinical trials for ITCA 650 (exenatide, delivered continuously once or...

Lilly To Discontinue Development Of Tabalumab Based On Efficacy Results In Phase 3 Lupus Studies

INDIANAPOLIS, Oct. 2, 2014 -- Eli Lilly and Company (NYSE: LLY) announced today it will discontinue development of tabalumab­ -- being studied for the treatment of systemic lupus erythematosus...

Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia

Esperion Therapeutics Announces Positive Top-Line Phase 2b Results for ETC-1002, An Investigational Therapy for Patients with Hypercholesterolemia - ETC-1002-008 study meets primary endpoint - -...

The Lancet Publishes Two Phase 3 Studies Showing Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Patients With Serious Genetic Disorders That Cause High Cholesterol

Data From Phase 3 RUTHERFORD-2 Study Show Evolocumab Significantly Reduced Mean LDL-C by 59-66 Percent Compared to Placebo in Patients With Heterozygous Familial Hypercholesterolemia

The Greek company “ANTAEA Medical Services Ltd.” won the lawsuit against “ATLAS Medical Services Ltd.” and Özdemir Hiçdurmaz

The Greek company "ANTAEA Medical Services Ltd." won the lawsuit against "ATLAS Medical Services Ltd." and Özdemir Hiçdurmaz for unfair competition, in the Turkish...

Zafgen Announces Initiation of Phase 3 Trial of Beloranib in Prader-Willi Syndrome

BOSTON, Oct. 1, 2014 -- Zafgen, Inc. (ZFGN), a biopharmaceutical company dedicated to significantly improving the health and well-being of patients affected by obesity and complex metabolic...

LSP RAISES EUR 80 MLN TO INVEST IN MEDICAL INNOVATIONS

LSP (Life Sciences Partners) today announced that it has raised EUR 80 mln (USD 100 mln) for its new fund LSP 5. This fund will continue LSP's proven and successful strategy of investing in...

Portola Pharmaceuticals Announces Phase 3 ANNEXA(TM)-A Study of Andexanet Alfa and Eliquis (Apixaban) Met Primary and Secondary Endpoints With High Statistical Significance

Detailed Data Showing Andexanet Alfa Significantly Reversed Anticoagulation Activity of Factor Xa Inhibitor Eliquis to be Featured at American Heart Association's "Clinical Science: Special...

Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis

WATERTOWN, Mass., October 1, 2014 — Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the...

Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease...

Sarepta Therapeutics Announces Favorable Safety Results from Phase I Clinical Study of Influenza Drug Candidate

CAMBRIDGE, Mass.--Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced favorable safety results from the single ascending dose portion of a...

Pfizer And Kyowa Hakko Kirin To Collaborate On Immuno-Oncology Combination Study

Pfizer Inc. (PFE) and Kyowa Hakko Kirin (Tokyo:4151), announced today that they have entered into an agreement to explore the therapeutic potential of the combination of Pfizer's PF-05082566, an...

GSK commits further funding to advance bioelectronics research with creation of $5 million Innovation Challenge Fund

GSK today announced a $5 million Innovation Challenge Fund (ICF) to further encourage and advance collaborative research as part of its effort to develop bioelectronic medicines. The fund will...

Nimbus Discovery Appoints Donald Nicholson, Ph.D. as Chief Executive Officer

Nimbus Discovery Appoints Donald Nicholson, Ph.D. as Chief Executive Officer -- Critical hire at time of major transformation in the company's evolution – Cambridge, Mass. – September...

Johnson & Johnson Announces Agreement To Acquire Alios BioPharma

NEW BRUNSWICK, N.J., Sept. 30, 2014 -- Johnson & Johnson today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused...

Regeneron and Sanofi Announce Positive Phase 2 Top-line Dupilumab Results in Patients with Chronic Sinusitis with Nasal Polyps

TARRYTOWN, N.Y. and PARIS, Sept. 30, 2014 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of...

Mucosis Presents Infectious Diseases Vaccines Pipeline Update at SACHs Associates 14th Annual Biotech in Europe Forum

Fern Lazar/Danielle Lewis+1.212.867.1762orSue Charles/AUS: +61 (0) 466 924218Daniel Gooch/UK: +44 (0) 20 7866 7905

MacroGenics and Takeda Enter Second Strategic Alliance to Develop Multiple Additional DART Therapeutics

ROCKVILLE, Maryland and OSAKA, Japan - September 29, 2014 - MacroGenics, Inc.MGNX, +2.77% and Takeda Pharmaceutical Company Limited jointly announced today that they have entered into a collaboration...